Antimoniotungstate (HPA 23) treatment of three patients with AIDS and one with prodrome.

W Rozenbaum, D Dormont, B Spire - 1985 - cabidigitallibrary.org
Abstract [Many inorganic hydroxides can be copolymerized to form heteropolyanions.] HPA
23 is one such, derived from tungsten and antimony; its constitution is ammonium 21-tungsto …

Inhibition of replication of human immunodeficiency virus by a heteropolyoxotungstate (PM-19)

Y INOUYE, Y TAKE, Y TOKUTAKE… - Chemical and …, 1990 - jstage.jst.go.jp
A Keggin polyoxotungstate PM-l9 K7 [PTi2N1004o]-6H20 was found to be a potent inhibitor
of the replication of human immunodeficiency virus (HIV), which causes acquired …

Inhibition of RNA-dependent DNA polymerases of AIDS and SAIDS retroviruses by HPA-23 (ammonium-21-tungsto-9-antimoniate)

D Dormont, B Spire, F Barre-Sinoussi… - Annales de l'Institut …, 1985 - Elsevier
We report the action of HPA-23 on RNA-dependent DNA polymerases of two primate
retroviruses thought to be involved in acquired immune deficiency syndrome (AIDS) …

Antiviral therapy in AIDS: Clinical pharmacological properties and therapeutic experience to date

EG Sandström, JC Kaplan - Drugs, 1987 - Springer
The rapid spread of human immunodeficiency virus (HIV) infections and the grim outcome of
these infections have focused interest on the possibilities for medical intervention. The end …

Inhibition of proliferation of human immunodeficiency virus type 1 by novel heteropolyoxotungstates in vitro

Y Take, Y Tokutake, Y Inouye, T Yoshida, A Yamamoto… - Antiviral research, 1991 - Elsevier
Fifteen heteropolyoxotungstates were tested for their effects on the proliferation of human
immunodeficiency virus type 1 (HIV-1) using an in vitro system consisting of MT-4 cells and …

Anti-HIV-1 activity of inorganic polyphosphates

B Lorenz, J Leuck, D Köhl, WEG Müller… - JAIDS Journal of …, 1997 - journals.lww.com
Human blood plasma, serum, peripheral blood mononuclear cells, and erythrocytes contain
significant amounts of inorganic polyphosphates (ranging from 53 to 116 µM, in terms of …

[PDF][PDF] Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents.

N Yamamoto, D Schols, E De Clercq, Z Debyser… - Molecular …, 1992 - Citeseer
Various polyoxometalates proved inhibitory to the replication of a number of enveloped DNA
and RNA viruses, ie, herpesviruses (herpes simplex and cytomegalo), togaviruses(Sindbis) …

Clinical trial of tolerance of HPA-23 in patients with acquired immune deficiency syndrome

BL Moskovitz - Antimicrobial agents and chemotherapy, 1988 - Am Soc Microbiol
An open-label, multicenter clinical trial assessed the tolerance of HPA-23 (ammonium-21-
tungsto-9-antimoniate) in patients with acquired immune deficiency syndrome. Sixty-nine …

In vitro Antimyxovirus and Anti-Human Immunodeficiency Virus Activities of Polyoxometalates

S Shigeta, S Mori, J Watanabe… - Antiviral Chemistry …, 1995 - journals.sagepub.com
Polyoxometalates have been shown to inhibit the replication of retro-, toga-, paramyxo-and
herpesviruses. The primary mechanism of the anti-human immunodeficiency virus type 1 …

Suramin antiviral therapy in the acquired immunodeficiency syndrome: Clinical, immunologic, and virologic results

AM LEVINE, PS GILL, J COHEN… - Annals of internal …, 1986 - acpjournals.org
The human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV)
requires reverse transcriptase for viral replication. We treated 12 patients who had acquired …